Discontinuation (procedure)
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges
Cargo Therapeutics Discontinues Lead CAR-T Program Due to Poor Durability and Safety Concerns
CAR-T therapy, durability, safety, clinical trial discontinuation, large B-cell lymphoma, firi-cel, CARGO Therapeutics
Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication
Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny
Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts
Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology
HilleVax Discontinues Norovirus Vaccine for Infants After Mid-Stage Trial Failure
HilleVax, norovirus vaccine, infants, mid-stage trial, failure, discontinuation
Merck KGaA Discontinues Xevinapant Program for Locally Advanced Head and Neck Cancer
Merck KGaA, Xevinapant, Head and Neck Cancer, Phase III Trial, Discontinuation, Cancer Treatment
Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial
Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.
Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events
Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations